• Deborah and Tara join the lab. They will work on B-cell receptor signaling and mobility in CLL. Welcome!

  • Christine nails the hypomethylation of NFATC1, a major effector in the B-cell receptor signaling cascade that is so central to the pathomechanism of chronic lymphocytic leukemia. This explains at least in part why this pathway is so strongly active. Excellent work!

  • We write a commentary on the first comprehensive description of the different resistancies that can develop in CLL patients that are treated with the new magic bullet, ibrutinib, a BTK inhibtor: "unwanted and unwonted!"

  • Michael joins the lab. His expertise is on CRISPR, and he will take a closer look at signaling and chromatin of CLL. A real asset for the lab, very welcome!

to top